Literature DB >> 33992803

Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection.

Cory J Knudson1, Pedro Alves-Peixoto2, Hiromi Muramatsu3, Colby Stotesbury1, Lingjuan Tang1, Paulo J C Lin4, Ying K Tam4, Drew Weissman3, Norbert Pardi3, Luis J Sigal5.   

Abstract

It is well established that memory CD8 T cells protect susceptible strains of mice from mousepox, a lethal viral disease caused by ectromelia virus (ECTV), the murine counterpart to human variola virus. While mRNA vaccines induce protective antibody (Ab) responses, it is unknown whether they also induce protective memory CD8 T cells. We now show that immunization with different doses of unmodified or N(1)-methylpseudouridine-modified mRNA (modified mRNA) in lipid nanoparticles (LNP) encoding the ECTV gene EVM158 induced similarly strong CD8 T cell responses to the epitope TSYKFESV, albeit unmodified mRNA-LNP had adverse effects at the inoculation site. A single immunization with 10 μg modified mRNA-LNP protected most susceptible mice from mousepox, and booster vaccination increased the memory CD8 T cell pool, providing full protection. Moreover, modified mRNA-LNP encoding TSYKFESV appended to green fluorescent protein (GFP) protected against wild-type ECTV infection while lymphocytic choriomeningitis virus glycoprotein (GP) modified mRNA-LNP protected against ECTV expressing GP epitopes. Thus, modified mRNA-LNP can be used to create protective CD8 T cell-based vaccines against viral infections.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD8 T cells; lipid nanoparticle; mRNA vaccine; modified mRNA; poxvirus; virus

Mesh:

Substances:

Year:  2021        PMID: 33992803      PMCID: PMC8417516          DOI: 10.1016/j.ymthe.2021.05.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  52 in total

1.  Soluble interferon-gamma receptors encoded by poxviruses.

Authors:  A Alcamí; G L Smith
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1996-09       Impact factor: 2.268

2.  Biosynthesis of the IFN-gamma binding protein of ectromelia virus, the causative agent of mousepox.

Authors:  Hongdong Bai; R Mark L Buller; Nanhai Chen; Michael Green; Anthony A Nuara
Journal:  Virology       Date:  2005-03-30       Impact factor: 3.616

3.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

4.  CD94 is essential for NK cell-mediated resistance to a lethal viral disease.

Authors:  Min Fang; Mark T Orr; Pieter Spee; Thomas Egebjerg; Lewis L Lanier; Luis J Sigal
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

5.  Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking.

Authors:  Min Fang; Felicia Roscoe; Luis J Sigal
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

6.  A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA.

Authors:  Markus Baiersdörfer; Gábor Boros; Hiromi Muramatsu; Azita Mahiny; Irena Vlatkovic; Ugur Sahin; Katalin Karikó
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-27

7.  The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination.

Authors:  Ren-Huan Xu; Matthew Cohen; Yong Tang; Eric Lazear; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Luis J Sigal
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

8.  A Thermostable mRNA Vaccine against COVID-19.

Authors:  Na-Na Zhang; Xiao-Feng Li; Yong-Qiang Deng; Hui Zhao; Yi-Jiao Huang; Guan Yang; Wei-Jin Huang; Peng Gao; Chao Zhou; Rong-Rong Zhang; Yan Guo; Shi-Hui Sun; Hang Fan; Shu-Long Zu; Qi Chen; Qi He; Tian-Shu Cao; Xing-Yao Huang; Hong-Ying Qiu; Jian-Hui Nie; Yuhang Jiang; Hua-Yuan Yan; Qing Ye; Xia Zhong; Xia-Lin Xue; Zhen-Yu Zha; Dongsheng Zhou; Xiao Yang; You-Chun Wang; Bo Ying; Cheng-Feng Qin
Journal:  Cell       Date:  2020-07-23       Impact factor: 41.582

9.  Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.

Authors:  Philip C LaTourette; Sita Awasthi; Angela Desmond; Norbert Pardi; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641

10.  A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.

Authors:  Dorottya Laczkó; Michael J Hogan; Sushila A Toulmin; Philip Hicks; Katlyn Lederer; Brian T Gaudette; Diana Castaño; Fatima Amanat; Hiromi Muramatsu; Thomas H Oguin; Amrita Ojha; Lizhou Zhang; Zekun Mu; Robert Parks; Tomaz B Manzoni; Brianne Roper; Shirin Strohmeier; István Tombácz; Leslee Arwood; Raffael Nachbagauer; Katalin Karikó; Jack Greenhouse; Laurent Pessaint; Maciel Porto; Tammy Putman-Taylor; Amanda Strasbaugh; Tracey-Ann Campbell; Paulo J C Lin; Ying K Tam; Gregory D Sempowski; Michael Farzan; Hyeryun Choe; Kevin O Saunders; Barton F Haynes; Hanne Andersen; Laurence C Eisenlohr; Drew Weissman; Florian Krammer; Paul Bates; David Allman; Michela Locci; Norbert Pardi
Journal:  Immunity       Date:  2020-07-30       Impact factor: 43.474

View more
  5 in total

Review 1.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

2.  An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.

Authors:  Manon Ripoll; Marie-Clotilde Bernard; Céline Vaure; Emilie Bazin; Sylvie Commandeur; Vladimir Perkov; Katia Lemdani; Marie-Claire Nicolaï; Patrick Bonifassi; Antoine Kichler; Benoit Frisch; Jean Haensler
Journal:  Biomaterials       Date:  2022-05-07       Impact factor: 15.304

Review 3.  Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era.

Authors:  Nicola Borbone; Ilaria Piccialli; Andrea Patrizia Falanga; Vincenzo Piccialli; Giovanni N Roviello; Giorgia Oliviero
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

Review 4.  The nano delivery systems and applications of mRNA.

Authors:  Mingyuan Li; Yuan Li; Shiqin Li; Lin Jia; Haomeng Wang; Meng Li; Jie Deng; Ali Zhu; Liqiao Ma; Weihong Li; Peng Yu; Tao Zhu
Journal:  Eur J Med Chem       Date:  2021-10-08       Impact factor: 6.514

5.  Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System.

Authors:  Gokulnath Mahalingam; Hari Krishnareddy Rachamalla; Porkizhi Arjunan; Yogapriya Periyasami; Salma M; Saravanabhavan Thangavel; Kumarasamypet M Mohankumar; Mahesh Moorthy; Shaji R Velayudhan; Alok Srivastava; Srujan Marepally
Journal:  Front Pharmacol       Date:  2022-03-25       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.